Forte Biosciences (FBRX) Invested Capital (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Invested Capital data on file, last reported at $42.1 million in Q1 2026.

• Invested Capital for Q1 2026 came in at $42.1 million, up 9.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $42.1 million (up 9.56% YoY), and the FY2025 annual result was $61.0 million, up 16.22% from the prior year.
• Invested Capital retreated to $42.1 million in Q1 2026 per FBRX's latest filing, from $61.0 million in the prior quarter.
• Over five years, Invested Capital peaked at $98.6 million in Q2 2025 and troughed at $9.4 million in Q3 2024.
• A 5-year average of $42.7 million and a median of $38.8 million in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2024 and 2025: Invested Capital tumbled 76.82% in 2024, then soared 797.9% in 2025.
• A 5-year view of Invested Capital shows it stood at $38.8 million in 2022, then retreated by 9.03% to $35.3 million in 2023, then surged by 48.61% to $52.5 million in 2024, then climbed by 16.22% to $61.0 million in 2025, then slumped by 30.97% to $42.1 million in 2026.
• Business Quant data shows FBRX's Invested Capital at $42.1 million in Q1 2026, $61.0 million in Q4 2025, and $84.1 million in Q3 2025.